1. Home
  2. Stocks
  3. Neclife Share Price

Nectar Lifesciences Share Price

Pharmaceuticals Small Cap

₹38.89 -0.09 (-0.23%)

05 Nov, 2024 17:26

SIP TrendupStart SIP in NECLIFE

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹39
  • High
  • ₹39
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹57
  • Open Price₹0
  • Previous Close₹40
  • Volume103,247

Investment Returns

  • Over 1 Month -7.27%
  • Over 3 Month + 22.91%
  • Over 6 Month + 12.89%
  • Over 1 Year + 67.63%
SIP Lightning

Smart Investing Starts Here Start SIP with Nectar Lifesciences for Steady Growth!

Nectar Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 142
  • PEG Ratio
  • 1.2
  • Market Cap Cr
  • 872
  • P/B Ratio
  • 0.8
  • Average True Range
  • 2.16
  • EPS
  • 0.2
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.48
  • RSI
  • 56.56
  • MFI
  • 49.57

Nectar Lifesciences Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations359.30439.85452.17397.96394.12
Total Income From Operations359.30441.37452.17397.96394.12
P/L Before Interest, Excpt. Items & Tax24.8935.2827.3022.1620.68
P/L Before Exceptional Items & Tax4.9211.122.461.643.06
P/L After Tax from Ordinary Activities2.970.601.571.021.82
Net Profit/Loss For the Period2.970.601.571.021.82
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,925.831,746.56
Revenue From Operations [Net]1,684.091,523.67
Total Operating Revenues1,684.091,523.67
Total Revenue1,698.661,566.85
Total Expenses1,680.391,607.54
Profit/Loss Before Tax18.28-40.69
Profit/Loss For The Period5.00-22.46
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity224.69133.37
Net Cash Used In Investing Activity-17.0352.03
Net Cash Used in Finance Activity-205.44-185.57
Net Inc/Dec In Cash And Equivalent2.23-0.17
Cash And Equivalent End Of Year19.8017.57
IndicatorMar 24Mar 23
Total Share Capital22.4322.43
Total Non-Current Liabilities148.99233.69
Total Current Liabilities972.82890.93
Total Capital And Liabilities2,191.062,189.21
Total Non-Current Assets729.29771.99
Total Current Assets1,461.771,417.22
Total Assets2,191.062,189.21
Indicator20242023
EBIT Margin (%)6.252.54
Return On Capital Employed (%)8.652.98
Return On Equity (%)0.46-2.10
Long Term Debt To Equity (%)13.1221.27
Book Value/Share (INR)47.6847.47
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations359.30439.85452.17397.96394.12
Total Income From Operations359.30441.37452.17397.96394.12
P/L Before Interest, Excpt. Items & Tax24.8935.2727.3022.1620.68
P/L Before Exceptional Items & Tax4.9211.112.461.643.06
P/L After Tax from Ordinary Activities2.970.591.571.021.82
Net Profit/Loss For the Period2.970.591.571.021.82
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,925.831,746.56
Revenue From Operations [Net]1,684.091,523.67
Total Operating Revenues1,684.091,523.67
Total Revenue1,698.661,566.85
Total Expenses1,680.391,609.27
Profit/Loss Before Tax18.27-42.42
Profit/Loss For The Period5.00-24.18
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity224.69133.65
Net Cash Used In Investing Activity-17.0351.70
Net Cash Used in Finance Activity-205.44-185.58
Net Inc/Dec In Cash And Equivalent2.23-0.23
Cash And Equivalent End Of Year19.8117.58
IndicatorMar 24Mar 23
Total Share Capital22.4322.43
Total Non-Current Liabilities148.99233.69
Total Current Liabilities972.82890.93
Total Capital And Liabilities2,191.062,189.21
Total Non-Current Assets729.28771.99
Total Current Assets1,461.771,417.23
Total Assets2,191.062,189.21
Indicator20242023
EBIT Margin (%)6.252.43
Return On Capital Employed (%)8.652.85
Return On Equity (%)0.46-2.27
Long Term Debt To Equity (%)13.1221.27
Book Value/Share (INR)47.6847.47

Nectar Lifesciences Technicals

EMA & SMA

Current Price
₹38.89
-0.09 (-0.23%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹37.46
  • 50 Day
  • ₹38.31
  • 100 Day
  • ₹37.23
  • 200 Day
  • ₹34.95

Resistance and Support

39.06 Pivot Speed
  • R3 43.13
  • R2 41.56
  • R1 40.63
  • S1 38.13
  • S2 36.56
  • S3 35.63

Is Nectar Lifesciences Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nectar Lifesciences manufactures and supplies pharmaceuticals, active pharmaceutical ingredients (APIs), and herbal products. With state-of-the-art facilities in India, the company serves global markets, focusing on healthcare, wellness, and life-saving medications for various therapeutic segments. Nectar Lifesciences has an operating revenue of Rs. 1,650.81 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 6% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Nectar Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-15 Audited Results
2024-02-14 Quarterly Results
2023-11-10 Quarterly Results

Nectar Lifesciences F&O

Nectar Lifesciences Shareholding Pattern

55.8%
3.24%
30.45%
10.51%
  • NSE Symbol
  • NECLIFE
  • BSE Symbol
  • 532649
  • Chairman & Managing Director
  • Mr. Sanjiv Goyal
  • ISIN
  • INE023H01027

Nectar Lifesciences FAQs

Nectar Lifesciences share price is ₹38 As on 05 November, 2024 | 17:12

The Market Cap of Nectar Lifesciences is ₹872.2 Cr As on 05 November, 2024 | 17:12

The P/E ratio of Nectar Lifesciences is 142 As on 05 November, 2024 | 17:12

The PB ratio of Nectar Lifesciences is 0.8 As on 05 November, 2024 | 17:12

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.